- A global clinical trial, involving The Hospital for Sick Children (SickKids), has found that mavacamten safely and effectively improves blood flow in the left ventricles of youth with hypertrophic cardiomyopathy (HCM).
- This heart medication, previously approved for adults, marks a significant breakthrough as the first phase 3 trial of its kind for pediatric HCM, as reported by SickKids.ca.
- The positive findings from this study were published in the New England Journal of Medicine and presented at the American College of Cardiology's Annual Scientific Session, according to National Today.
- Pharmacy Times noted that mavacamten significantly reduced blood flow obstruction and improved cardiac biomarkers in symptomatic adolescents.
- This successful trial could potentially help many young patients avoid the need for invasive open-heart surgery, offering a new precision medicine approach, as highlighted by PR Newswire.
Mavacamten Reduces Obstructive HCM in Youth
A global clinical trial has revealed that mavacamten, a heart medication previously approved for adults, safely and effectively improves blood flow in the left ventricles of youth with hypertrophic cardiomyopathy. This groundbreaking finding, the first phase 3 trial of its kind for pediatric HCM, offers a precision medicine approach that could help many young patients avoid invasive open-heart surgery.
Report an issue with this article
Please sign in to report issues with this article.
Live discussion about this article
Comments
Comments are disabled for this article.
